Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375440 | 0.89 | MAPT (0.67) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| SCHEMBL86392 | 0.89 | MAPT (0.67) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| Butyric Acid SCHEMBL3359947 | 0.85 | AKR1B1 (0.59) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| 3-Methylbutanoic Acid SCHEMBL3359773 | 0.84 | AKR1B1 (0.57) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| Ethyl Acetate SCHEMBL3359951 | 0.84 | ALDH1A1 (0.61) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| Valeric Acid SCHEMBL9879921 | 0.83 | AKR1B1 (0.56) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| Acetic Acid SCHEMBL28502663 | 0.82 | MAOA (0.77) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| Acetic Acid SCHEMBL28227973 | 0.81 | MAOA (0.74) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| SCHEMBL8882817 | 0.80 | AKR1B1 (0.56) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 | |
| SCHEMBL10922029 | 0.80 | TTR (0.55) | MAPTALDH1A1SMN1; SMN2RAB9AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55108834-A | — | — | None | — | — | JP | disclosed |
| EP-2393797-B1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM SPA (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-8835655-B2 | Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof | ZACH SYSTEM S.P.A (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2012-01-19 | — | — | US | disclosed |
| EP-2393797-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZaCh System S.p.A. (IT) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089268-A2 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZACH SYSTEM S.P.A. (IT) | 2010-08-12 | — | — | WO | disclosed |
| EP-0119540-B1 | SUBSTITUTED ALKYLAMINE DERIVATIVES OF 6,11-DIHYDRO-11-OXODIBENZ (B,E)-OXEPINS, A PROCESS FOR THE PREPARATION AND INTERMEDIATES THEREOF AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-08-22 | — | — | EP | disclosed |
| US-4751238-A | ANALGESICS, ANTIINFLAMMATORY AGENT | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-06-14 | — | — | US | disclosed |
| US-4576960-A | 6,11-Dihydro-11-oxo-dibenz[b,e]oxepin derivatives | HOECHST ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-03-18 | — | — | US | disclosed |
| US-4515946-A | 6,11-Dihydro-11-oxo-dibenz-[b,e]oxepin derivatives | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0082521-A1 | 6,11-Dihydro-11,-oxo-dibenz(b,e)-oxepin derivatives, methods for their preparation, pharmaceutical compositions containing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-29 | — | — | EP | disclosed |
| JP-S55108834-A | PREPARATION OF (2-CARBOXYBENZYLOXY)-PHENYLACETATIC ACID | DAI ICHI SEIYAKU CO LTD | 1980-08-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016138-A1 | PROCESS FOR PREPARING OLOPATADINE AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | QDPR, OPRD1, O60361 | MAPT 2063/4885ALDH1A1 1057/4885SMN1; SMN2 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.